Back to mobile site

More on VERU

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+38.0% Growth)
- Ratings (8.9 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Veru, Inc. (NQ:VERU)
Delayed: 3.04 +0.08 (2.70%)
Prev. Close $2.96  
Open$2.91 
52 Wk High$ 
52 Wk Low$ 
Day High$3.07 
Day Low$2.91 
P/E N/A  
EPS$ 
Volume341,653 


Jun 4, 2026 01:03 PM Oppenheimer Reiterates Outperform Rating on Veru, Inc. (VERU)
Jun 4, 2026 08:42 AM Veru partners with Novo Nordisk for obesity drug combination study
Jun 4, 2026 08:30 AM Form 8-K VERU INC. For: Jun 02
May 15, 2026 07:48 AM Veru, Inc. (VERU) PT Lowered to $24 at Oppenheimer
May 13, 2026 09:20 AM Form S-8 VERU INC.
May 13, 2026 09:10 AM Form 10-Q VERU INC. For: Mar 31
May 13, 2026 07:00 AM Form 8-K VERU INC. For: May 13
May 13, 2026 06:41 AM Veru, Inc. (VERU) Misses Q2 EPS by 13c
May 13, 2026 06:30 AM Veru reports second quarter fiscal 2026 results and obesity trial update
May 13, 2026 06:30 AM Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
View All Articles

Entities mentioned with VERU

View All Entities